ElectroCore

ElectroCore is a medical technology company headquartered in Basking Ridge, New Jersey, focused on neuromodulation therapies delivered through external electrical stimulation. Its principal technology is non-invasive vagus nerve stimulation, intended to influence neural pathways without requiring an implanted device or an invasive surgical procedure. The company’s best-known product is gammaCore, a handheld stimulation system designed for application to the neck over the vagus nerve. The company was founded in 2005 by JP Errico, Thomas J. Errico, Charles Theofilos, and Peter Staats. Its development strategy centered on translating vagus nerve stimulation into commercially usable, non-invasive products. Unlike implanted vagus nerve stimulators, ElectroCore’s platform is externally applied and can be used by patients or caregivers according to the relevant product instructions and regulatory indication. This approach positioned the company in the intersection of medical devices, neurological care, pain management, respiratory applications, and consumer-oriented electrical stimulation. ElectroCore’s primary commercial platform has been gammaCore. The product has been associated with treatment or prevention of certain headache conditions and with other clinical applications depending on the specific model and regulatory authorization. In July 2020, the United States Food and Drug Administration granted emergency authorization for gammaCore Sapphire CV for a respiratory application involving people potentially affected by COVID-19 who had difficulty breathing because of asthma. The authorization illustrated the company’s effort to extend its neuromodulation technology into acute and respiratory-care settings, although emergency authorization is distinct from ordinary full-market approval for a general indication. The company became publicly traded in 2018 through an initial public offering that raised approximately $78 million. In March 2020, ElectroCore announced a common-stock purchase agreement allowing it to sell up to $25 million of stock to Lincoln Park Capital Fund, an institutional investor. These transactions gave the company additional financing capacity while it continued commercializing its devices and funding research, regulatory, and market-development activities. ElectroCore has also marketed Truvaga, a vagus nerve stimulation product aimed at a broader wellness and consumer audience. In 2025, the company acquired NeuroMetrix, adding the Quell electrical nerve stimulation platform to its portfolio. The transaction expanded ElectroCore beyond its original vagus-nerve-centered identity and broadened its exposure to externally delivered electrical nerve stimulation products. ElectroCore’s business remains centered on medical and wellness technologies rather than pharmaceuticals. Its competitive proposition is based on non-invasive delivery, portability, and the possibility of using electrical neuromodulation outside a hospital or operating room. Its commercial and regulatory outlook depends on clinical evidence, reimbursement and healthcare adoption, product-specific authorizations, manufacturing, and the company’s ability to establish durable demand for both clinician-directed and consumer-facing stimulation products.

ElectroCore was established in 2005 by JP Errico, Thomas J. Errico, Charles Theofilos, and Peter Staats. The founders pursued a non-invasive approach to vagus nerve stimulation, a field historically associated with implanted devices as well as research into neurological, pain, and autonomic conditions. ElectroCore’s central proposition was that electrical stimulation could be delivered externally through a handheld device, potentially allowing treatment to be administered without implantation or surgery. The company developed gammaCore as its principal commercial platform. gammaCore is a non-invasive vagus nerve stimulation device applied to the neck. Its development and commercialization placed ElectroCore within the medical-device sector, with activities spanning clinical research, regulatory submissions, physician engagement, patient access, and product distribution. The product has been associated with headache-related applications and other uses depending on the particular model and regulatory status. A major corporate turning point came in 2018, when ElectroCore completed an initial public offering. The offering was reported at approximately $78 million and made the company a Nasdaq-listed public issuer under the ticker ECOR. Public-market access provided a financing and visibility mechanism for a company still investing in clinical development, regulatory work, commercialization, and operating infrastructure. On March 27, 2020, ElectroCore announced a common-stock purchase agreement with Lincoln Park Capital Fund, a Chicago-based institutional investor. The arrangement provided for potential purchases of up to $25 million of common stock. It was announced during a period in which many medical technology companies were seeking liquidity and flexibility amid the disruption caused by the COVID-19 pandemic. In July 2020, the FDA granted emergency authorization to gammaCore Sapphire CV for a respiratory application. The authorization was directed at reducing exacerbations in people potentially affected by the novel coronavirus who had difficulty breathing due to asthma. This represented an expansion of the platform’s public-health relevance beyond its established neuromodulation and headache-related positioning. Because the authorization was issued under an emergency framework, it should be understood as a product-specific regulatory action rather than evidence that every gammaCore model or indication received the same authorization. ElectroCore later expanded its portfolio with Truvaga, a vagus nerve stimulation product associated with a broader consumer and wellness proposition. Truvaga extended the company’s use of vagus nerve stimulation beyond a narrowly clinician-directed device model, although the applicable product claims and regulatory context differ by market and product version. In 2025, ElectroCore acquired NeuroMetrix. The transaction added the Quell electrical nerve stimulation platform and broadened the company’s portfolio from a primary focus on non-invasive vagus nerve stimulation to a wider group of electrical nerve stimulation technologies. The acquisition represents a strategic effort to build scale and diversify product exposure within neuromodulation and externally delivered electrical stimulation. ElectroCore’s history is therefore defined by four linked developments: founding around non-invasive vagus nerve stimulation, commercialization of the gammaCore platform, access to public and institutional financing, and portfolio expansion through consumer products and the NeuroMetrix acquisition. The company’s future performance depends on clinical support, regulatory permissions, reimbursement, physician and patient adoption, consumer demand, and its ability to integrate and commercialize the acquired Quell platform.

• 2025

  NeuroMetrix acquisition

  [1]ElectroCoreen.wikipedia.org

  ElectroCore acquired NeuroMetrix and added the Quell electrical nerve stimulation platform to its portfolio.

• 2020

  Lincoln Park Capital financing agreement

  [1]ElectroCoreen.wikipedia.org

  The company announced a common-stock purchase agreement allowing Lincoln Park Capital Fund to purchase up to $25 million of common stock.

• 2020

  Emergency authorization for gammaCore Sapphire CV

  [1]ElectroCoreen.wikipedia.org

  The FDA granted emergency authorization for a respiratory use involving people potentially affected by COVID-19 who had difficulty breathing due to asthma.

• 2018

  Initial public offering

  [1]ElectroCoreen.wikipedia.org

  ElectroCore completed an IPO reported at approximately $78 million and began trading on Nasdaq under the ECOR ticker.

• 2005

  ElectroCore is founded

  [1]ElectroCoreen.wikipedia.org

  JP Errico, Thomas J. Errico, Charles Theofilos, and Peter Staats co-founded the company to develop non-invasive neuromodulation technologies.

ElectroCore positions itself as a neuromodulation and medical-device company offering externally applied electrical stimulation therapies, particularly non-invasive vagus nerve stimulation, as alternatives or complements to drug-based treatment and implanted stimulation systems.

• Non-invasive vagus nerve stimulation device

  gammaCore

  gammaCore is ElectroCore’s principal handheld neuromodulation platform. It delivers electrical stimulation externally at the neck over the vagus nerve, avoiding an implanted generator and surgical implantation. The platform has been associated with headache-related care and other clinical applications, with the precise use depending on the model, market, and applicable regulatory authorization.

• Respiratory-use vagus nerve stimulation device · 2020

  gammaCore Sapphire CV

  gammaCore Sapphire CV is a version of the gammaCore platform that received FDA emergency authorization in July 2020 for a respiratory application involving people potentially affected by COVID-19 who had difficulty breathing due to asthma. Its authorization was specific to the emergency-use context and should not be generalized to all gammaCore products or indications.

• Consumer vagus nerve stimulation product

  Truvaga

  Truvaga is an ElectroCore-owned vagus nerve stimulation product associated with a broader consumer and wellness-oriented proposition. It uses externally delivered stimulation rather than an implanted system. Product claims, intended use, and availability depend on the relevant market and product documentation.

• Electrical nerve stimulation platform

  Quell

  Quell is an electrical nerve stimulation platform obtained through ElectroCore’s 2025 acquisition of NeuroMetrix. The acquisition broadened ElectroCore’s portfolio beyond vagus nerve stimulation and added another externally delivered electrical stimulation technology to its neuromodulation offering.

• 2025

  Acquisition of NeuroMetrixM&A

  Background

  ElectroCore sought to broaden its neuromodulation portfolio beyond non-invasive vagus nerve stimulation.

  Action taken

  The company acquired NeuroMetrix and added the Quell electrical nerve stimulation platform.

  Aftermath

  The transaction expanded ElectroCore’s product portfolio and increased its exposure to externally delivered electrical nerve stimulation technologies.

  Source

• 2020

  Common-stock purchase agreement with Lincoln Park CapitalOther

  Background

  The company sought additional financing flexibility during a period of intense uncertainty for healthcare businesses.

  Action taken

  ElectroCore announced an agreement under which Lincoln Park Capital Fund could purchase up to $25 million of the company’s common stock.

  Aftermath

  The agreement created a potential source of additional equity capital, although the reference material does not establish the amount ultimately drawn.

  Maximum common-stock purchase commitment. $25 million (Announced March 27, 2020)

  Source

• 2020

  Emergency authorization for gammaCore Sapphire CVProduct launch

  Background

  The COVID-19 pandemic created demand for potential adjunctive technologies addressing respiratory complications and exacerbations.

  Action taken

  The FDA granted emergency authorization for gammaCore Sapphire CV for a specified respiratory application involving people potentially affected by COVID-19 and experiencing difficulty breathing due to asthma.

  Aftermath

  The authorization expanded the platform’s emergency-use profile into respiratory care, while remaining distinct from a general authorization for every product or indication.

  Source

• 2018

  Public listing through an initial public offeringOther

  Background

  ElectroCore needed public-market capital and visibility while developing and commercializing its neuromodulation products.

  Action taken

  The company completed an IPO reported at approximately $78 million and became listed on Nasdaq under ECOR.

  Aftermath

  The transaction established ElectroCore as a public medical-technology company and provided a source of financing for continued operations and product development.

  Initial public offering proceeds. $78 million (2018 IPO)

  Source

1. 1ElectroCoreen.wikipedia.org